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Abstract 
Background: Differentiating Ventilator‑Associated Tracheobronchitis (VAT) from Ventilator‑Associated Pneumonia 
(VAP) may be challenging for clinicians, yet their management currently differs. In this study, we evaluated the accu‑
racy of the Clinical Pulmonary Infection Score (CPIS) to differentiate VAT and VAP.
Methods: We performed a retrospective analysis based on the data from 2 independent prospective cohorts. 
Patients of the TAVeM database with a diagnosis of VAT (n = 320) or VAP (n = 369) were included in the derivation 
cohort. Patients admitted to the Intensive Care Centre of Lille University Hospital between January 1, 2016 and 
December 31, 2017 who had a diagnosis of VAT (n = 70) or VAP (n = 139) were included in the validation cohort. The 
accuracy of the CPIS to differentiate VAT from VAP was assessed within the 2 cohorts by calculating sensitivity and 
specificity values, establishing the ROC curves and choosing the best threshold according to the Youden index.
Results: The areas under ROC curves of CPIS to differentiate VAT from VAP were calculated at 0.76 (95% CI [0.72–0.79]) 
in the derivation cohort and 0.67 (95% CI [0.6–0.75]) in the validation cohort. A CPIS value ≥ 7 was associated with the 
highest Youden index in both cohorts. With this cut‑off, sensitivity and specificity were respectively found at 0.51 and 
0.88 in the derivation cohort, and at 0.45 and 0.89 in the validation cohort.
Conclusions: A CPIS value ≥ 7 reproducibly allowed to differentiate VAT from VAP with high specificity and PPV and 
moderate sensitivity and NPV in our derivation and validation cohorts.
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Background
Ventilator-Associated Lower Respiratory Tract Infections 
(VA-LRTI), including Ventilator-Associated Tracheo-
bronchitis (VAT) and Ventilator-Associated Pneumonia 
(VAP), are the most frequent infectious complications 
in Intensive Care Units (ICU), concerning about 25% of 
critically ill subjects undergoing mechanical ventilation 
[1]. Their diagnosis currently relies on symptoms of 
lower respiratory tract infection in patients intubated for 
more than 48 h with a positive culture of lower respira-
tory microbiological sampling. In addition to these crite-
ria, the presence of a new infiltrate on chest radiography 
allows to make the diagnosis of VAP. By contrast, VAT 
is characterized by the combination of the above-men-
tioned criteria without new radiographic infiltrates [2].
The occurrence of VAP is associated with increased 
mortality, longer duration of mechanical ventilation 
and length of stay in the ICU. On the other hand, the 
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diagnosis of VAT seems to be linked with lower levels of 
mortality than VAP, even though being associated with 
increased length of mechanical ventilation and ICU stay 
[1]. The management of VAP currently relies on anti-
microbial therapy, whereas current guidelines do not 
recommend the administration of antibiotics in VAT, 
making the distinction between these two entities a cru-
cial point [2].
Although theoretically based on clearly defined crite-
ria, differentiating VAT and VAP may sometimes be chal-
lenging for the physician. Indeed, chest radiographies 
performed in the context of ICU often lead to multiple 
artefacts, additionally to numerous causes of non-infec-
tious radiological opacities making the diagnosis of VAP 
tricky. In addition, a lack of sensitivity of chest radiog-
raphy has been reported for the detection of VAP, thus 
leading to a likely underestimation of this diagnosis in 
mechanically ventilated patients [3–5].
Several tools have been developed to improve the 
detection of VAP. Amongst them, the Clinical Pulmonary 
Infection Score (CPIS) is a daily routine parameter-based 
score with moderate to good accuracy in the detection of 
VAP. This score, originally described by Pugin et al, has 
been declined in a simplified version, allowing its easier 
appliance by physicians at patient’s bedside [6, 7]. Based 
on the results of a single study, recent guidelines on the 
management of Hospital-Acquired Pneumonia and VAP 
suggest that a CPIS score ≤ 6 should lead to the early dis-
continuation of antimicrobial therapy, being associated 
with a low probability of pneumonia [2, 8].
Considering these observations, the use of the CPIS 
in patients with microbiologically confirmed VA-LRTI 
might be proposed as a helpful tool for the early detec-
tion of VAP. However, to the best of our knowledge, the 
evaluation of the CPIS in this indication has never been 
reported yet and would be of significant interest. Fur-
thermore, such an evaluation should be preferentially 
performed in 2 independent cohorts to assess its repro-
ducibility, given the heterogeneity in the performances of 
CPIS for the diagnosis of VAP in ventilated patients [9], 
and because this score was not initially developed to dis-
tinguish VAT from VAP.
Therefore, we aimed in this study to evaluate the accu-
racy of the CPIS to differentiate VAT from VAP in 2 




This is a retrospective study based on the analysis from 
the TAVeM database [1] and of a cohort of patients 
admitted in a single mixed ICU during a 2-year period.
The TAVeM study is a large prospective multinational 
observational study conducted in 114 ICUs in Europe 
and South America. Details about the design and patients 
of the TAVeM study have been previously published [1].
In our study, patients from the TAVeM database with 
a diagnosis of VA-LRTI were included in the derivation 
cohort.
Patients admitted in the single mixed ICU of the Lille 
University Hospital between 1 January 2016 and 31 
December 2017 and with a diagnosis of VA-LRTI were 
included in the validation cohort.
Data collection
Patient demographic characteristics, severity scores, 
comorbidities, primary diagnoses, and prior antibiotic 
exposure were recorded at baseline for all patients. Fur-
ther, data about clinical, biological and radiological diag-
nostic criteria for VA-LRTI, microbiological diagnostic 
procedures, bacteriological findings, degree of severity 




The diagnosis of VA-LRTI was based on the presence of 
at least 2 of the following criteria: body temperature of 
more than 38.5  °C or less than 36.5  °C, leucocyte count 
greater than 12,000 cells per μL or less than 4 000 cells 
per μL, and purulent endotracheal aspirate. Microbiolog-
ical confirmation was needed for all episodes of infection, 
with the isolation in the endotracheal aspirate of at least 
 105 CFU per mL, or in bronchoalveolar lavage of at least 
 104 CFU per mL.
VAT was defined with the above-mentioned criteria 
with no radiographical signs of new pneumonia. Con-
versely, VAP was defined by the presence of new or pro-
gressive infiltrates on chest radiograph.
CPIS
A modified version of the CPIS was used in this study, as 
previously published in the literature (Additional file  1) 
[7]. Notably, we did not consider cultures of tracheal 
aspirate; leucocyte categories were reduced to two; three 
categories were used for the aspect of sputum; tracheal 
secretions were classified as few, moderate, large, and 
purulent. The CPIS score was calculated at the time of 
microbiological sampling for clinical suspicion of VA-
LRTI by retaining for each variable the maximal attribut-
able number of points over the 24 past hours.
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Outcomes
The primary aim of this study was to evaluate the accu-
racy of the CPIS to differentiate VAT from VAP in 
patients with microbiologically confirmed VA-LRTI.
Statistical analysis
Categorical variables were expressed as numbers (per-
centages) and compared using Chi square test or Fisher’s 
exact test, as appropriate. Normality of distribution of 
continuous variables was checked graphically and using 
the Shapiro–Wilk test. Skewed continuous variables 
were presented as medians (interquartile ranges), and 
compared using Mann–Whitney U tests. Normally dis-
tributed continuous variables were presented as means 
(SD), and compared using Student’s t tests. Correlations 
between skewed continuous variables were assessed 
using Spearman’s rank correlation tests, and regres-
sion lines were displayed using simple linear regression 
method.
To assess the diagnostic ability of CPIS to differenti-
ate VAT from VAP, we performed a Receiver Operating 
Characteristics (ROC) analysis for the diagnosis of VAP 
in both derivation and validation cohorts. We computed 
the area under the ROC curve (AUC) and the sensitivity, 
specificity, positive and negative predictive values (PPV 
and NPV) as well as positive and negative likelihood 
ratios for different cut-off values. The best cut-off for the 
discrimination between VAP and VAT was determined 
according to the Youden index.
All statistical tests were two-tailed and p values < 0.05 
were considered statistically significant. Statistics 
Department of Lille University Hospital performed all 
data analyses using SAS software package, release 9.4 
(SAS Institute, Cary, NC, USA).
Results
Three hundred twenty patients with VAT and 369 
patients with VAP were included in the derivation 
cohort. Seventy patients with VAT and 136 patients with 
VAP were included in the validation cohort.
Percentage of male and percentage of cirrhosis were 
higher, whilst age was lower in patients with VAP com-
pared to patients with VAT in the derivation cohort. 
SOFA score was higher and percentage of heart failure 
was lower in patients with VAP compared to patients 
with VAT in the validation cohort. Appropriate ini-
tial antimicrobial therapy was more frequent in VAP 
than in VAT in the derivation cohort, and less frequent 
in VAP compared to VAT in the validation cohort 
(Table  1).  Comparisons of baseline patients characteris-
tics between derivation and validation cohorts are shown 
in Additional file 2. 
Table 1 Baseline characteristics of patients
Data are presented as number (%) or mean (SD)
COPD Chronic obstructive pulmonary disease, SAPS Simplified acute physiology score, SOFA Sequential organ failure assessment, VAP Ventilator-associated 
pneumonia, VAT Ventilator-associated tracheobronchitis
p value < 0.05 is indicated in italic characters
Derivation cohort P value Validation cohort P value
VAT (n = 320) VAP (n = 369) VAT (n = 70) VAP (n = 136)
Sex
 Male 199 (62%) 264 (72%) 51 (73%) 102 (75%)
 Female 121 (38%) 105 (28%) 0.009 19 (27%) 34 (25%) 0.74
Age (years) 61.20 (16.25) 57.74 (18.46) 0.009 55.26 (16.1) 54.98 (16.36) 0.89
SAPS II 48.85 (18.12) 49.89 (17.80) 0.45 54.6 (19.46) 59.97 (16.68) 0.079
SOFA 7.64 (3.79) 8.07 (3.63) 0.13 7.19 (4.34) 8.9 (4.04) 0.008
Admission category
 Medical 175 (55%) 218 (59%) 57 (81%) 117 (86%)
 Surgical 145 (45%) 151 (41%) 0.25 13 (19%) 19 (14%) 0.39
 COPD 64 (20%) 61 (17%) 0.24 6 (10%) 21 (15%) 0.17
 Diabetes mellitus 66 (21%) 69 (19%) 0.53 14 (20%) 26 (20%) 0.88
 Immunocompromised patients 24 (8%) 31 (8%) 0.66 7 (10%) 23 (17%) 0.18
 Chronic heart failure 27 (8%) 19 (5%) 0.085 16 (23%) 16 (12%) 0.037
 Chronic respiratory failure 35 (11%) 27 (7%) 0.098 3 (4%) 7 (5%) 0.78
 Cirrhosis 8 (2%) 23 (6%) 0.018 3 (4%) 10 (7%) 0.38
 Previous antibiotic use 210 (66%) 232 (63%) 0.45 60 (86%) 107 (79%) 0.3
 Appropriate initial antimicrobial therapy 174 (54%) 257 (70%) < 0.001 40 (57%) 55 (40%) 0.023
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Clinical outcomes in the derivation and validation 
cohorts are shown in Table 2 and Additional file 3. ICU 
mortality was higher in patients with VAP compared to 
patients with VAT in the derivation cohort.
The analysis of microbiological findings revealed a 
higher frequency of Enterobacter spp. in patients with 
VAP compared to patients with VAT in the validation 
cohort. Conversely, Citrobacter freundii was found more 
frequently in VATs than in VAPs in the validation cohort 
(Table  3). Comparisons of microbiological findings 
between derivation and validation cohorts are shown 
in Additional file 4. CPIS values ranged from 0 to 10 for 
patients with VAT and from 0 to 11 for patients with VAP 
in the derivation cohort. In the validation cohort, CPIS 
values ranged from 2 to 10 for patients with VAT and 
from 1 to 10 for patients with VAP.
The distribution of CPIS values was significantly lower 
in patients with VAT than in those with VAP in the deri-
vation cohort with median values of 4 (3–6) vs 7 (5–8) 
(p < 0.0001) as well as in the validation cohort (5 (4–6) vs 
6 (5 –7) (p < 0.0001)) (Fig. 1).
ROC analysis showed AUCs at 0.76 (95% CI [0.72–
0.79]) in the derivation cohort and 0.67 (95% CI [0.6–
0.75]) in the validation cohort (Fig. 2).
Performances of the CPIS for the diagnosis of VAP 
at different cut-offs are summarized in Table  4. A CPIS 
value ≥ 7 was associated with the highest Youden index 
in both cohorts. With this cut-off, sensitivity and speci-
ficity were respectively found at 0.51 and 0.88 in the 
derivation cohort, and at 0.45 and 0.89 in the validation 
cohort. A CPIS value  ≥ 7 was found in 225 patients of the 
validation cohort and amongst them, 187 were true VAPs 
(PPV = 0.83). In the derivation cohort, 69 patients had 
Table 2 Clinical outcomes of patients
Data are presented as number (%) or median (interquartile range)
ICU Intensive Care Unit; VAP Ventilator-Associated Pneumonia; VAT Ventilator-Associated Tracheobronchitis
p values < 0.05 are indicated in italics characters
Derivation cohort P value Validation cohort P value
VAT (n = 320) VAP (n = 369) VAT (n = 70) VAP (n = 136)
Days on mechanical ventilation 13 (8–20) 13 (8–26) 0.35 18 (13–29) 17 (11–29) 0.23
Days in the ICU 21 (15–34) 22 (13–36) 0.69 24 (16 – 37) 22 (14–35) 0.3
ICU mortality 93 (29%) 146 (40%) 0.004 18 (26%) 46 (34%) 0.23
Progression from VAT to VAP 39 (12%) – – 7 (10%) – –
Table 3 Microbiological findings
Data are presented as number (%) or mean (SD)
COPD Chronic obstructive pulmonary disease, MSSA Methicillin-sensitive Staphylococcus Aureus, MRSA Methicillin-resistant Staphylococcus Aureus, SAPS Simplified 
acute physiology score, SOFA Sequential organ failure assessment, VAP Ventilator-associated pneumonia, VAT Ventilator-associated tracheobronchitis
p values < 0.05 are indicated in italic characters
Derivation cohort P value Validation cohort P value
VAT (n = 320) VAP (n = 369) VAT (n = 70) VAP (n = 136)
Streptococcus pneumoniae 16 (5%) 24 (7%) 0.41 2 (3%) 5 (4%) 1
Stenotrophomonas maltophila 19 (6%) 12 (3%) 0.09 4 (6%) 6 (4%) 0.74
MRSA 8 (2%) 8 (2%) 0.77 1 (1%) 1 (1%) 1
MSSA 66 (21%) 80 (22%) 0.73 6 (9%) 21 (15%) 0.17
Serratia marcescens 12 (4%) 16 (4%) 0.69 3 (4%) 5 (4%) 1
Pseudomonas aeruginosa 79 (25%) 89 (24%) 0.86 20 (29%) 29 (21%) 0.25
Proteus mirabilis 15 (5%) 14 (4%) 0.56 3 (4%) 5 (4%) 1
Klebsiella pneumoniae 48 (15%) 53 (14%) 0.81 9 (13%) 30 (22%) 0.11
Haemophilus influenzae 32 (10%) 25 (7%) 0.12 4 (6%) 6 (4%) 0.74
Escherichia coli 37 (12%) 40 (11%) 0.76 5 (7%) 9 (7%) 1
Enterobacter spp. 35 (11%) 46 (12%) 0.53 4 (6%) 21 (15%) 0.043
Citrobacter freundii 7 (2%) 6 (2%) 0.58 4 (6%) 1 (1%) 0.047
Acinetobacter baumannii 14 (4%) 27 (7%) 0.10 0 (0%) 2 (1%) 0.55




































Fig. 1 Values of CPIS in patients with VAT and VAP in the derivation (a) and validation (b) cohorts. Box plot shows the median (horizontal line) 
and IQR (25th 75th percentile) (box). The whiskers show the lowest data within 1.5 IQR of the lower quartile and highest data within 1.5 IQR of 
the upper quartile. Data outside 1.5 IQR of the upper or lower quartiles are depicted with a dot. CPIS Clinical Pulmonary Infection Score; VAP 






















Fig. 2 ROC curves of CPIS for the diagnosis of VAP amongst patients with VA LRTI in the derivation (a) and validation (b) cohorts. A sensitivity 
analysis was performed for the accuracy of CPIS in diagnosing VAP amongst patients with VA LRTI and ROC curves were computerized in derivation 
and validation cohorts. CPIS Clinical pulmonary infection score, VAP Ventilator‑associated pneumonia, VAT Ventilator‑associated tracheobronchitis, 
VA LRTI Ventilator‑associated lower respiratory tract infection
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a CPIS value  ≥ 7 and amongst them 61 were true VAPs 
(PPV = 0.83) (Fig. 3).
In the derivation cohort, inappropriate antimi-
crobial therapy was associated with a longer dura-
tion of mechanical ventilation in patients with a CPIS 
value  ≥ 7, whilst no difference between groups was 
found in subjects with a CPIS value  < 7 (Table 5). Com-
parisons of clinical outcomes according to the appro-
priateness of antimicrobial therapy in VAT and VAP in 
derivation and validation cohorts are shown in Addi-
tional file 5.
Discussion
In this study, a CPIS value  ≥ 7 appeared as the best cut-
off according to the Youden index, with a high speci-
ficity and a moderate sensitivity, with similar results in 
both derivation and validation cohorts.
As far as we know, this is the first study to explore 
the accuracy of CPIS for the diagnosis of VAP amongst 
patients with VA-LRTI. CPIS has been widely described 
as a helpful tool, with a moderate accuracy for the diag-
nosis of VAP, a best cut-off value of 6 in most studies, 
and pooled estimates for sensitivity and specificity at 
0.65 and 0.64, respectively [9].
The question of early identifying patients who will 
develop a diagnosis of VAP may be critical, as thera-
peutic managements of VAT and VAP currently dif-
fer. Indeed, current guidelines recommend that VAP 
Table 4 Performances of CPIS for the diagnosis of VAP in patients with VA-LRTI
CPIS Clinical pulmonary infection score, Se Sensitivity, Sp Specificity, PPV Positive predictive value, NPV Negative predictive value, LR + Positive likelihood ratio, LR- 
Negative likelihood ratio
CPIS value Se Sp PPV NPV LR+ LR- Youden index
Derivation cohort ≥ 5 0.83 0.51 0.66 0.72 1.68 0.34 0.34
≥ 6 0.68 0.69 0.71 0.65 2.17 0.46 0.37
≥ 7 0.51 0.88 0.83 0.61 4.13 0.56 0.39
Validation cohort ≥ 5 0.78 0.34 0.70 0.44 1.19 0.64 0.12
≥ 6 0.60 0.70 0.80 0.48 2 0.57 0.3


































Fig. 3 Scatter dot plots of CPIS in patients with VAT and VAP in the derivation (a) and validation (b) cohorts relatively to the 7‑point cut‑off. The CPIS 
value is depicted as a single dot for each patient. Dash lines separate patients with a CPIS value ≥ 7 from those with a CPIS value < 7. CPIS Clinical 
pulmonary infection score, VAP Ventilator‑associated pneumonia, VAT Ventilator‑associated tracheobronchitis
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should be treated with appropriate antimicrobial ther-
apy, by contrast with VAT for which such a treatment 
remains not recommended [2, 10]. In that view, con-
sidering a CPIS value  ≥ 7 as a criterion for the early 
initiation of antimicrobial therapy may appear clini-
cally relevant, as this cut-off was associated with good 
specificities and PPVs > 0.8 in both cohorts. Further-
more, a CPIS value  ≥ 7 was found in 187/369 (51%) and 
61/136 (45%) patients with VAPs in our derivation and 
validation cohorts, respectively, suggesting that this 
threshold may allow an early diagnosis in almost half 
cases of VAP. Conversely, we may note the moderate to 
poor NPV of the CPIS to exclude the diagnosis of VAP. 
Accordingly, it appears that using the CPIS in subjects 
with clinical suspicion of VA-LRTI and positive micro-
biological sampling should mostly be considered for the 
early initiation of antibiotics in patients with a CPIS 
value  ≥ 7.
However, these considerations must be taken with cau-
tion. First, because appropriate antimicrobial therapy in 
patients with CPIS ≥ 7 was poorly associated with favour-
able outcomes in our cohorts, yet this result might be a 
consequence of the differences in characteristics between 
patients receiving appropriate and inappropriate antibi-
otic treatments. Second, the question of initiating anti-
biotic treatments in patients with VAT remains unclear. 
Indeed, a continuum between VAT and VAP cannot be 
ruled out, as a higher risk of pneumonia was reported in 
patients with VAT in the TAVeM study [1]. In addition, 
data from this cohort suggest that the risk of progression 
from VAT to VAP would be reduced in patients receiving 
antibiotic treatment. On the other hand, current French 
and international guidelines do not address the initiation 
of antibiotics in VAT, because of a lack of evidence sup-
porting this strategy [2]. Thus, further investigations are 
warranted to clarify whether patients with VAT should 
benefit or not from antimicrobial therapy.
One apparently surprising result of our study was 
the 25% rate of patients with CPIS values  ≥ 6 in VATs. 
This might be explained by the fact that our study was 
restricted to patients with symptoms of lower respira-
tory tract infections. This is likely to have resulted in 
overall greater CPIS values in our population than usu-
ally reported, especially in patients without VAP [9]. As a 
consequence, a more intense clinical presentation seems 
required to accurately segregate VAPs from VATs than 
to distinguish VAPs from patients without respiratory 
infections. This might partly explain the optimal cut-off 
found at 7 in our study, which is higher than the 6 points 
threshold usually reported in the literature [9].
In contrast, we report CPIS values found at 0 or 1 in 
several patients with VAPs and VATs in both cohorts. 
This result is actually reflecting the uncomplete clini-
cal presentations initially observed in some patients. 
In these, the symptoms could initially include a mild 
increase of body temperature without reaching 38.5  °C, 
the appearance of few tracheal secretions, or a moder-
ate worsening of the  PaO2/FiO2 ratio without falling 
below 240, thus motivating the respiratory microbio-
logical sampling, although the CPIS was still calculated 
at 0 or 1 by then. However, all these patients eventually 
reached the criteria for VA-LRTI, with a worsening of 
their symptoms, thus completing their clinical presenta-
tion. This frequent progression at the initial stage of VA-
LRTI raises the question of whether the calculation of 
CPIS at a single time-point can give enough information 
to distinguish VAP from VAT. The evaluation of the rela-
tionship between CPIS calculated at the time of clinical 
suspicion of VA-LRTI and variations of CPIS over 24  h 
before that time-point (Delta CPIS) in our derivation 
Table 5 Comparisons of clinical outcomes according to the value of CPIS and appropriateness of antimicrobial therapy
Data are presented as number (%) or median (interquartile range)
ICU Intensive care unit; CPIS Clinical pulmonary infection score
p values < 0.05 are indicated in italic characters







P value Appropriate 
antimicrobial 








< 7 14 (8–26) 13 (8–24) 0.59 17.5 (11–32.5) 19 (12–28) 0.82
≥ 7 14 (8–26) 18 (12–29.5) 0.03 16 (11–33) 17 (11–26.5) 0.72
Days in the ICU < 7 21 (13–31) 21.5 (14–36) 0.37 24 (14.5–36) 25 (14–36.5) 0.76
≥ 7 19 (13–32) 25 (15–40.5) 0.052 20 (13–30) 20 (15–41) 0.77
ICU mortality < 7 88 (33%) 65 (34%) 0.93 19 (30%) 23 (32%) 0.82
≥ 7 62 (38%) 24 (28%) 0.12 7 (23%) 15 (39%) 0.13
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cohort brings some interesting insights about that ques-
tion. This analysis reveals that nearly all patients with a 
CPIS value ≥ 7 also had a Delta CPIS ≥ 0 and that CPIS 
was subsequently correlated to Delta CPIS in VAT and 
in VAP (Additional file 6). Furthermore, Delta CPIS does 
not seem to show greater accuracy than CPIS to differ-
entiate VAT from VAP (Additional file  7). These results 
convey the idea that subjects with greater CPIS are not 
only exhibiting marked features of respiratory infection, 
but are also worsening their symptoms, thus supporting 
the reliability of the CPIS measured at a single time-point 
to discriminate VATs from VAPs.
Other parameters than the CPIS might be proposed to 
improve the early diagnosis of VAP. VAP seemed to be 
associated with a higher mortality in ICU than VAT, yet 
this result was not statistically significant in the valida-
tion cohort. This result suggests that a diagnosis of VAP 
might be associated with more severe organ failures, and 
especially with more severe levels of hypoxaemia. This 
hypothesis is supported by the results of the TAVeM 
study, showing that significantly more patients with VAP 
had an episode of worsening gas exchange than did those 
with VAT [1]. Therefore, severity scores like SOFA, cal-
culated at the time of the clinical suspicion of VA-LRTI, 
could help to improve the early detection of VAP, par-
ticularly through evaluation of the respiratory SOFA. A 
similar strategy has already been developed through the 
Infection Probability Score, although this score does not 
apply specifically to VAP but to nosocomial infections in 
general [11]. Furthermore, such a strategy has never been 
evaluated specifically for VA-LRTI.
Routine biomarkers like CRP and PCT have been 
evaluated for the identification of VAP, with variable 
diagnostic performances. Luyt et  al. reported a poor 
accuracy of PCT for the diagnosis of VAP, with ROC 
AUCs respectively found at 0.51 and 0.62 for D-1 PCT 
and PCT increase. To be noted that adjunction of PCT 
did not significantly improve the accuracy of the CPIS 
for the diagnosis of VAP in this study, with an AUC ris-
ing from 0.68 for CPIS alone to 0.69 for CPIS combined 
with PCT [12]. In another report, Charles et al. showed 
good performances of PCT variations for the diagnosis of 
nosocomial infections, with AUCs > 0.8 in ROC analysis 
and similar results for the diagnosis of VAP. In this work, 
PCT variations were above all associated with a good 
specificity and high PPVs [13]. On the other hand, Povoa 
et  al. showed a moderate performance of CRP for the 
diagnosis of VAP, with AUCs > 0.7 for variations of CRP 
in their ROC analysis [14]. Furthermore, at the day of 
VAP diagnosis, they observed that a single measurement 
of CRP was useful in particular for the exclusion of VAP 
diagnosis. Beside these routine biomarkers, some authors 
have investigated the potential usefulness of sTREM-1, 
yet with disappointing results showing very poor accu-
racy for the diagnosis of VAP [15, 16].
These data underline the potential utility of these bio-
markers in differentiating VAT from VAP. However, their 
moderate accuracy when taken as single parameter high-
lights the hypothetical interest of a mixed evaluation 
integrating one or several of these variables in a CPIS-
based score.
The distinction between VAT and VAP currently relies 
on the presence of at least one new infiltrate on the chest 
radiography. However, the relevance of this criterion 
remains questionable, given its low accuracy in diagnos-
ing microbiologically confirmed VAP amongst critically 
ill subjects undergoing mechanical ventilation [3]. This 
inaccuracy mainly results from the difficulties to distin-
guish infiltrates of infectious cause from other aetiolo-
gies, like pleural effusions, cardiac overload or atelectasis, 
which are frequently present in ICU patients [4]. In that 
view, lung ultrasound has been proposed as a promising 
tool for the diagnosis of VAP, and could thus be consid-
ered to distinguish VAT from VAP, yet its utility remains 
limited because of its poor inter-operator reproducibility 
[17]. Computed tomography (CT) could also be proposed 
to enhance the detection of lung infiltrates. Indeed, Self 
et al. reported that only 43.5% of the patients presenting 
to ED with opacities on CT had images of pneumonia 
detected on chest radiography [18]. Therefore, CT could 
allow a better differentiation between VAT and VAP. 
However, its greater cost, associated with the necessity 
to transport patients, and higher exposure to radiations 
limit its use in routine clinical practice. All these tools 
could improve the accuracy of the CPIS and should prob-
ably be assessed in a future updated version of this score.
Our study has several limitations. First, this was a 
retrospective analysis, thus limiting the parameters 
that could be studied in our cohorts. Above all, study-
ing the accuracy of inflammation biomarkers like CRP 
or PCT would have been interesting, but could not be 
performed because these parameters were not meas-
ured in a sufficient number of patients in our validation 
cohort. Second, this study was performed in patients 
with microbiologically confirmed VA-LRTI, limiting 
the applicability of our results at the patient’s bedside, 
because of the frequent delay between processing of the 
microbiological sampling and culture positivity. Third, 
evaluating the CPIS to distinguish VAT from VAP 
might appear questionable in our study, as the radio-
graphic criterion is part of the items required for the 
calculation of this score. Nevertheless, it must be noted 
that the CPIS was calculated once for all at the time 
of microbiological sampling in the respiratory tract, 
which corresponded to the moment of the clinical 
suspicion of VA-LRTI. This is to oppose the methods 
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used to retrospectively classify patients between VAT 
and VAP, with all the biological, clinical and radiologi-
cal data available to make a final diagnosis. This last 
point must be considered regarding the frequency of 
uncomplete initial presentation with initial absence of 
radiographic signs, representing more than 60% of VAP 
in the study performed by Ramirez et  al. [5]. Fourth, 
the population of our study included a lower percent-
age of surgical admissions in the validation cohort than 
in the derivation cohort. This might have interfered 
with our results, as a poor accuracy of CPIS has been 
reported in surgical patients, because non-infectious 
causes of lung injury may represent a confounder in 
this population [19, 20]. Fifth, the rates of appropriate 
initial antibiotic treatments were significantly different 
between VAPs and VATs in both cohorts. Accordingly, 
we could not draw any conclusion regarding the benefit 
of appropriate antimicrobial therapy in patients with 
a CPIS value ≥ 7. Sixth, ROC analysis showed a lower 
AUC of CPIS in our validation cohort, thus under-
lining a weaker overall accuracy in this population. 
Finally, lung infiltrates were probably missed in some 
patients with VAP, given the reported lack of sensitiv-
ity of chest radiography for the detection of pneumonia 
[3, 4]. However, the use of chest radiography allowed 
us to diagnose VAT and VAP using the same criteria 
than in the TAVeM study. Accordingly, our definitions 
of VAP and VAT are consistent with those in which a 
difference in mortality rates was reported [1]. Further 
explorations in a larger prospective multicentre study 
are needed to confirm our findings.
Conclusions
In patients with evidence of VA-LRTI, a CPIS value  ≥ 7 
allowed the early diagnosis of half cases of VAP with 
specificity and PPV above 80% in our derivation and 
validation cohorts. The CPIS might thus be considered 
as a helpful tool to drive the early initiation of antimi-
crobial therapy in patients with VA-LRTI.
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